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the ROTEM®; Clotting Time (CT), Clot Formation Time (CFT), α-angle, 
Maximum Clot Firmness (MCF) were analyzed.
Results: Rivaroxaban and dabigatran, prolonged the CT but did not 
significantly alter the CFT, the α-angle and the MCF. At equivalent 
gravimetric concentrations dabigatran effect was more pronounced 
compared to rivaroxaban. When the two agents were combined no 
amplificatory effect on CT was observed. The α-angle and MCF were 
not significantly affected. Tinzaparin induced a significant prolon-
gation of CT and CFT and reduced the α-angle and MCF values as 
compared to the control. Tinzaparin impact was significantly more 
potent than the DOAC combination used even at the higher studied 
concentrations.
Conclusions: When coagulation is triggered by physiologically rel-
evant concentrations of TF, rivaroxaban and dabigatran prolong the 
CT, did not alter fibrin polymerization kinetics nor clot firmness. The 
combination of rivaroxaban and dabigatran did not alter clot forma-
tion process suggesting that the important effect of tinzaparin on clot 
formation quality is not linked to its anti-Xa or anti-IIa activity associa-
tion but most probably is related to a direct interference with fibrin 
network and others antithrombin dependent inhibitory effects. 
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Background: Although direct oral anticoagulants (DOAC) do not re-
quire close laboratory monitoring, their measurement remains useful 
in specific clinical situations. A therapeutic range has not been defined 
yet, but DOAC plasma concentrations were shown to correlate with 
bleeding outcomes.
Aims: To describe DOAC plasma concentrations in patients with 
bleeding events, in relation to clinical and medication data.
Methods: As part of a prospective observational study conducted in 
the emergency departments of 2 hospitals, we collected 14 plasma 
samples from DOAC-treated patients admitted for bleeding events. 
Routine clotting assays were performed as well as specific assays 
using CE approved procedures (calibrated chromogenic anti-Xa as-
says for apixaban and rivaroxaban and diluted thrombin time and 
ecarin chromogenic assay for dabigatran). Clinical data were collected 
on admission, at discharge and at 90 days. Bleeding severity was as-
sessed using ISTH definition. The study was approved by the Ethics 
Committees.
Results: Patients (median age 75 years) were mainly treated with ri-
varoxaban (10/14), for stroke prevention in atrial fibrillation (10/14). 
The most frequent site of bleeding was gastrointestinal (6/14). Seven 
bleedings were major (table 1).
Conclusions: A large range of DOAC plasma concentrations was ob-
served, with above on-therapy levels estimated in around half of pa-
tients admitted for bleeding events. Among the factors contributing 
to bleeding, potential drug interactions are frequent in anticoagulated 
patients and should be screened. 
T A B L E  1 Patient characteristics, management of bleeding and biological measurements for major bleeding events
Gender, 
age (years)
CLcr (ml/
min)
DOAC (dosage, 
indication)
Time after 
last intake 
(hours)
Site of 
bleeding
DOAC plasma 
concentrations (ng/ml) Management
Length of 
stay (days)
Outcome at 
90 days
F, 70 Unknown Rivaroxaban 15 mg 
OD, SPAF
22 GI bleeding Biophen DiXaI: 237.5 RBC (3 units)* Unknown Unknown
F, 87 48 Rivaroxaban 20 mg 
OD, VTE
38 GI bleeding Biophen DiXaI: 70.8 RBC (2 units)* 3 Alive
F, 67 53 Rivaroxaban 20 mg 
OD, SPAF
27 GI bleeding Biophen DiXaI Low: 
58.3
RBC (3 units)* 1 Alive
F, 74 73 Apixaban 5 mg 
BID, SPAF
5 IC bleeding Biophen DiXaI: 298.0 - 9 Alive
F, 77 61 Rivaroxaban 15 mg 
OD, SPAF
27 IC bleeding Biophen DiXaI: 139.4 PCC 2500 IU 
(40 IU/kg)
43 Alive
F, 76 33 Dabigatran 
etexilate 110 mg 
BID, SPAF
53 GI bleeding HTI Low: 19.0 RBC (1 unit) 34 Alive
F, 90 60 Rivaroxaban 15 mg 
OD, SPAF
27 IC bleeding Biophen DiXaI: 86.5 - 1 Alive
* Transfusion before blood sampling. BID: twice daily, CLcr: creatinine clearance (according to Cockroft-Gault equation), Biophen DiXaI: Biophen® 
Direct Factor Xa Inhibitors, GI: gastrointestinal, HTI: Hemoclot Thrombin Inhibitor®, IC: intracranial, OD: once daily, PCC: prothrombin complex 
concentrates, RBC: red blood cells, SPAF: stroke prevention in atrial fibrillation, VTE: venous thromboembolism
